![]() ![]() Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements, including statements regarding the plans, intentions, beliefs and current expectations of the Company. The Novamind Shares will be delisted from the Canadian Securities Exchange ("CSE") and Novamind intends to submit an application to the applicable securities regulators to cease to be a reporting issuer and to terminate its public reporting obligations.įull details of the Transaction are described in the Company's management information circular dated May 6, 2022, which is available on the Company's SEDAR profile at Story continues Holders of Novamind restricted share units ("Novamind RSUs") received the number of Numinus Shares equal to the number of Novamind Shares such holder was entitled to under each Novamind RSU, subject to any withholdings or deductions, multiplied by the Exchange Ratio. In addition, each Novamind option has been exchanged for replacement Numinus options that entitle the holders to receive, upon exercise thereof, Numinus Shares based upon the Exchange Ratio. Pursuant to the Transaction, Numinus acquired all of the common shares of Novamind ("Novamind Shares") and the holders of Novamind Shares have received 0.84 (the "Exchange Ratio") of a common share of Numinus (each a "Numinus Share") for each Novamind Share held. (TSX:NUMI)(OTCQX:NUMIF) ("Numinus") by way of a plan of arrangement (the "Transaction") following receipt of a final order from the Supreme Court of British Columbia. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that the Company has completed its previously announced acquisition by Numinus Wellness Inc. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.TORONTO, ON / ACCESSWIRE / J/ Novamind Inc. ![]() Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Qualified investors can learn more about the Conference and register to schedule a one-on-one meeting with Novamind's management here. The corporate presentation will be available to registered Conference attendees for on-demand viewing beginning at 7:00 AM EST on September 13. Novamind's CEO and Director, Yaron Conforti, will present the Company's business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine. ![]() Wainwright 23 rd Annual Global Investment Conference ("the Conference"), taking place virtually on September 13-15, 2021. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the H.C. TORONTO, ON / ACCESSWIRE / Septem/ Novamind Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |